These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 35298000)
21. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Zhou Z; Yu L; Kleinerman ES Cancer; 2014 Feb; 120(4):579-88. PubMed ID: 24415532 [TBL] [Abstract][Full Text] [Related]
22. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530 [TBL] [Abstract][Full Text] [Related]
23. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
24. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. Adane B; Alexe G; Seong BKA; Lu D; Hwang EE; Hnisz D; Lareau CA; Ross L; Lin S; Dela Cruz FS; Richardson M; Weintraub AS; Wang S; Iniguez AB; Dharia NV; Conway AS; Robichaud AL; Tanenbaum B; Krill-Burger JM; Vazquez F; Schenone M; Berman JN; Kung AL; Carr SA; Aryee MJ; Young RA; Crompton BD; Stegmaier K Cancer Cell; 2021 Jun; 39(6):827-844.e10. PubMed ID: 34129824 [TBL] [Abstract][Full Text] [Related]
25. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012 [TBL] [Abstract][Full Text] [Related]
26. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151 [TBL] [Abstract][Full Text] [Related]
28. TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma. Seong BKA; Dharia NV; Lin S; Donovan KA; Chong S; Robichaud A; Conway A; Hamze A; Ross L; Alexe G; Adane B; Nabet B; Ferguson FM; Stolte B; Wang EJ; Sun J; Darzacq X; Piccioni F; Gray NS; Fischer ES; Stegmaier K Cancer Cell; 2021 Sep; 39(9):1262-1278.e7. PubMed ID: 34329586 [TBL] [Abstract][Full Text] [Related]
29. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472 [TBL] [Abstract][Full Text] [Related]
30. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076 [TBL] [Abstract][Full Text] [Related]
31. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491 [TBL] [Abstract][Full Text] [Related]
32. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Kinsey M; Smith R; Lessnick SL Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343 [TBL] [Abstract][Full Text] [Related]
33. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells. Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901 [TBL] [Abstract][Full Text] [Related]
34. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061 [TBL] [Abstract][Full Text] [Related]